What Is Retatrutide?

Overview

Retatrutide, also catalogued under the development code LY3437943, is a synthetic peptide investigated as a single molecule that activates three distinct metabolic receptors simultaneously. Where earlier incretin compounds engage one or two targets, retatrutide is studied as a "triple agonist" reaching the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Its structure carries amino-acid substitutions and a lipid side chain that extend its circulating half-life to roughly six days, a profile consistent with once-weekly dosing in the trials that have studied it.

How Retatrutide Works

Each of the three receptor arms contributes a different effect in research models. GLP-1 signalling is associated with glucose-dependent insulin secretion and reduced appetite; the GIP arm adds to the postprandial insulin response and may modulate how nutrients are handled; and glucagon-receptor activity is studied for its potential to raise energy expenditure and shift fat metabolism. The hypothesis behind combining all three in one molecule is that the glucagon component can amplify metabolic-rate and weight effects beyond what GLP-1 or GIP engagement alone produces, while the incretin arms help keep blood-glucose handling balanced. Retatrutide is frequently compared in the literature against single agonists (GLP-1 only) and dual agonists (GIP plus GLP-1) to isolate the contribution of the third receptor.

What the Research Explores

• Body-weight reduction and obesity endpoints across phase 2 and phase 3 trial programs.
• Glycemic control in type 2 diabetes, including A1C lowering and insulin dynamics.
• Metabolic dysfunction-associated steatotic liver disease (MASLD) and liver-fat content.
• Cardiometabolic markers such as blood pressure, lipid panels and waist circumference.
• Comparative pharmacology of triple-receptor engagement versus single- and dual-agonist designs.

Forms & Handling

In its clinical program retatrutide was administered as a once-weekly subcutaneous injection. There is no approved consumer formulation, and no official public-use vial size, concentration or reconstitution standard exists for it. Material encountered outside of a clinical setting cannot be assumed to match the investigational drug used in trials, and gray-market "vial math" should not be treated as equivalent. Any laboratory handling references should follow general peptide practice — lyophilized powder kept cold and dry, reconstituted only with appropriate sterile diluent for in-vitro work — rather than any clinical dosing schedule.

Safety & Research Notes

Retatrutide is an investigational compound. As of this writing it has no marketing approval for human or veterinary use, and any product offered outside an authorized clinical trial has no verified identity, purity or safety profile. Regulators have specifically cautioned against unapproved GLP-1-class products marketed for weight loss. Everything described on this page is mechanistic and research background only — it is not a usage recommendation and not medical advice.

References

Related Protocols